In addition to TP53 and ATM defects, chemoresistance might be a consequence of epigenetic and posttranscriptional factors or deregulations of other components of the DDR, because more than 50% of chemo-refractory CLL patients do not exhibit TP53 or ATM aberrations.5 This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.